Heterologous expression of a cardiomyopathic myosin that is defective in its actin interaction - PubMed (original) (raw)
. 1994 Jan 21;269(3):1603-5.
Affiliations
- PMID: 8294404
Free article
Heterologous expression of a cardiomyopathic myosin that is defective in its actin interaction
H L Sweeney et al. J Biol Chem. 1994.
Free article
Abstract
A point mutation in the heavy chain of cardiac myosin, resulting in replacement of an arginine (Arg) with glutamine (Gln), has been linked to hypertrophic cardiomyopathy in humans (Geisterfer-Lowrance, A. A. T., Kass, S., Tanigawa, G., Vosberg, H.-P., McKenna, W., Seidman, J. G., and Seidman, C. E. (1990) Cell 62, 999-1006). To determine the functional impact of this mutation, baculovirus-driven coexpression of myosin heavy and light chains has been developed. The Arg-403-->Gln mutation resulted in cardiac myosin with normal ATPase activity in the absence of actin. However, in the presence of actin, ATPase activity was greatly reduced (Vmax decreased > 3.5-fold and K(app) increased > 3-fold). In vitro motility was reduced nearly 5-fold by this single amino acid mutation. Thus, Arg-403 likely contributes to an important interaction at the actin interface of myosin. Replacement of Arg-403 with Gln leads to decreased rate(s) of transition within the actin-myosin crossbridge cycle. In humans, this mutation will result in decreased power output per unit area of cardiac muscle, likely providing a stimulus for hypertrophy.
Similar articles
- Hypertrophic cardiomyopathy R403Q mutation in rabbit β-myosin reduces contractile function at the molecular and myofibrillar levels.
Lowey S, Bretton V, Joel PB, Trybus KM, Gulick J, Robbins J, Kalganov A, Cornachione AS, Rassier DE. Lowey S, et al. Proc Natl Acad Sci U S A. 2018 Oct 30;115(44):11238-11243. doi: 10.1073/pnas.1802967115. Epub 2018 Oct 15. Proc Natl Acad Sci U S A. 2018. PMID: 30322937 Free PMC article. - Familial hypertrophic cardiomyopathic myosin mutations that affect the actin-myosin interaction.
Roopnarine O. Roopnarine O. Results Probl Cell Differ. 2002;36:75-86. doi: 10.1007/978-3-540-46558-4_7. Results Probl Cell Differ. 2002. PMID: 11892286 Review. No abstract available. - Regulation and kinetics of the actin-myosin-ATP interaction.
Adelstein RS, Eisenberg E. Adelstein RS, et al. Annu Rev Biochem. 1980;49:921-56. doi: 10.1146/annurev.bi.49.070180.004421. Annu Rev Biochem. 1980. PMID: 6447472 Review. No abstract available.
Cited by
- Identifying sarcomere gene mutations in hypertrophic cardiomyopathy: a personal history.
Seidman CE, Seidman JG. Seidman CE, et al. Circ Res. 2011 Mar 18;108(6):743-50. doi: 10.1161/CIRCRESAHA.110.223834. Circ Res. 2011. PMID: 21415408 Free PMC article. Review. - Functional analyses of troponin T mutations that cause hypertrophic cardiomyopathy: insights into disease pathogenesis and troponin function.
Sweeney HL, Feng HS, Yang Z, Watkins H. Sweeney HL, et al. Proc Natl Acad Sci U S A. 1998 Nov 24;95(24):14406-10. doi: 10.1073/pnas.95.24.14406. Proc Natl Acad Sci U S A. 1998. PMID: 9826713 Free PMC article. - Molecular genetics of cardiomyopathies.
Shah G, Roberts R. Shah G, et al. J Nucl Cardiol. 2000 Mar-Apr;7(2):159-70. doi: 10.1016/s1071-3581(00)90037-0. J Nucl Cardiol. 2000. PMID: 10796006 Review. No abstract available. - Mice expressing mutant myosin heavy chains are a model for familial hypertrophic cardiomyopathy.
Vikstrom KL, Factor SM, Leinwand LA. Vikstrom KL, et al. Mol Med. 1996 Sep;2(5):556-67. Mol Med. 1996. PMID: 8898372 Free PMC article. - Structural interpretation of the mutations in the beta-cardiac myosin that have been implicated in familial hypertrophic cardiomyopathy.
Rayment I, Holden HM, Sellers JR, Fananapazir L, Epstein ND. Rayment I, et al. Proc Natl Acad Sci U S A. 1995 Apr 25;92(9):3864-8. doi: 10.1073/pnas.92.9.3864. Proc Natl Acad Sci U S A. 1995. PMID: 7731997 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources